Innovative Herpes Virus-Based Vaccine Shows Potential in Cancer Treatment Without Side Effects
A novel herpes virus-based cancer vaccine shows promise in targeting tumors effectively without causing side effects, offering new hope for cancer therapies.
A groundbreaking study from Åbo Akademi University in Finland reveals that genetically modified herpes simplex virus can be engineered to act as an effective and safe cancer vaccine. Herpes simplex virus, commonly known for causing cold sores, is present in most individuals. Researchers have identified that by removing a specific virulence gene, which typically makes the virus harmful, the virus can be repurposed to target and destroy cancer cells without damaging healthy tissues.
This innovative approach involves inserting a gene that encodes decorin, a crucial protein involved in connective tissue regulation, wound healing, and blood vessel formation. Notably, decorin is often absent in many human cancers, including those characterized by excessive blood vessel growth or angiogenesis, which can hinder the effectiveness of traditional treatments. By restoring decorin expression within the vaccine, the therapy aims to inhibit tumor blood vessel formation, thereby starving the cancer and making it more susceptible to treatment.
Verifying its efficacy, the research demonstrated that decorin-enhanced vaccines significantly boosted the killing of lung cancer cells. Furthermore, these vaccines can be administered intranasally, which was successfully tested on mice, providing a less invasive delivery method. Remarkably, in chicken embryo models of liver cancer, the vaccine reduced tumor-associated blood vessel growth by 40%, with treated tumors developing normal vasculature, even after blood vessel formation had started. Importantly, no adverse side effects were observed, indicating the vaccine's specificity and safety.
Overall, these findings suggest a promising future for cancer vaccines that are not only effective but also free of side effects. By targeting blood vessel growth around tumors, such vaccines could improve drug delivery and treatment outcomes, potentially complementing existing therapies. This research paves the way for new, less invasive, and safer cancer treatment options.
Source: https://medicalxpress.com/news/2025-10-herpes-virus-based-vaccine-tumors.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Nirsevimab Shows Promise in Protecting Infants from RSV Lower Respiratory Tract Disease
A new study confirms that nirsevimab provides strong protection for infants against RSV-related lower respiratory tract disease, significantly reducing hospitalizations and healthcare visits during the RSV season.
New Insights into Cellular Communication in the Small Intestine of Celiac Disease Patients
Recent research has mapped the interactions of various cell types in the small intestine during celiac disease, offering new insights into disease mechanisms and potential therapies.
Emerging Role of Truncated Retrotransposon RNAs and Reverse Transcriptases in Aging Human Brain
New research uncovers how truncated LINE-1 RNAs encode active reverse transcriptases in the aging human brain, revealing potential targets for Alzheimer's therapy.
Innovative In Vitro Model Sheds Light on How Tumor Cells Enter the Bloodstream
A cutting-edge in vitro model reveals the detailed mechanism by which tumor cell clusters penetrate blood vessel walls and facilitate metastasis, paving the way for new targeted therapies against cancer spread.